Alumis Inc. (ALMS) vs Corvus Pharmaceuticals, Inc. (CRVS)
A side-by-side comparison of Alumis Inc. and Corvus Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALMS
Alumis Inc.
$6.78HealthcareDelayed quote: Oct 6, 2026, 2:25 PM EDT
CRVS
Corvus Pharmaceuticals, Inc.
$10.39HealthcareDelayed quote: Oct 6, 2026, 2:20 PM EDT
Total return — ALMS vs CRVS
growth of $100 · dividends reinvested · last 2yALMS -48.6% (-28.3%/yr)CRVS +474.3% (+139.7%/yr)CRVS compounded faster over this window
Log scale — wide-divergence pair
ALMS CRVS
ALMS vs CRVS: by the numbers
- •CRVS is the larger company ($873M vs $837M market cap).
- •Both run net losses; CRVS's is the smaller (0.00% vs -5933.45% net margin).
Metrics side by side
Valuation
| Metric | ALMS | CRVS |
|---|---|---|
| P/S ratio | 113.08 | N/A |
| P/B ratio | 1.85 | 3.88 |
Profitability
| Metric | ALMS | CRVS |
|---|---|---|
| Gross margin | 88.23% | 0.00% |
| Operating margin | -1776.32% | 0.00% |
| Net margin | -5933.45% | 0.00% |
| ROE | -97.08% | -24.02% |
| ROIC | -94.76% | -25.25% |
Growth (annualized)
| Metric | ALMS | CRVS |
|---|---|---|
| Total return CAGR (5Y) | N/A | 17.88% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.